A Next-Generation Sequencing-Based Assay for Hematologic Malignancies
Marcel R.M. van den Brink, MD, PhD, from Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies.
Clinical Pearls
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies. The analysis of the assay was presented at the 2013 ASH Annual Meeting. Information below reflects that of which was published in the abstract prior to the meeting.
- DNA and RNA were successfully extracted from specimens collected from 319 patients.
- 885 alterations were identified including (but not limited to) mutations inTP53,ASXL1,KRAS,NRAS,IDH2,TET2,SF3B1,JAK2,MLL2,DNMT3A,RUNX1, andSRSF2.
- The test demonstrated a high-level of accuracy at detecting gene substitutions, copy number alterations, insertions, and deletions.
View the full abstract > >
Checkpoint Inhibitors Deliver Longer OS in PPP2R1A-Mutated Endometrial Cancer vs Wild-Type Disease
April 7th 2025Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.
Read More
